Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

CEO Mike Doustdar shared the figure Monday at the J.P. Morgan Healthcare Conference, saying compounded versions have gained ...

Novo Nordisk CEO Mike Doustdar highlighted the growing use of compounded GLP-1 drugs in the U.S., which are cheaper but ...

Whether it’s due to an ingredient allergy or other reasons, compounding pharmacies can help tailor a custom-made medication to meet your needs. And when drug shortages happen, they can play an ...

The runaway popularity of GLP-1 medications like Ozempic and Wegovy for weight loss and diabetes management led to a nationwide shortage that lasted more than a year—and created the perfect conditions ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow compounding ...

The FDA has banned compounded versions of GLP-1 drugs like semaglutide or tirzepatide due to safety concerns, and supplies of these copycats are expected to drop. Compounded drugs can carry serious ...

Speaking at the J.P. Morgan Healthcare Conference, Doustdar said compounders recognized consumer behavior earlier than major ...

Many Americans have turned to compounding pharmacies to get popular weight-loss drugs due to lack of availability or expensive retail price tags. But this option will soon close for consumers. The ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...